15 results on '"Miwa, Shinji"'
Search Results
2. Reconstruction using a frozen autograft for a skull and humeral lesion of synchronous multicentric osteosarcoma after undergoing successful neoadjuvant chemotherapy: a case report and review of the literature
- Author
-
Araki, Yoshihiro, Hayashi, Katsuhiro, Yamamoto, Norio, Takeuchi, Akihiko, Miwa, Shinji, Igarashi, Kentaro, Higuchi, Takashi, Abe, Kensaku, Taniguchi, Yuta, Yonezawa, Hirotaka, Morinaga, Sei, Asano, Yohei, Nojima, Takayuki, and Tsuchiya, Hiroyuki
- Published
- 2021
- Full Text
- View/download PDF
3. Efficacy of perioperative chemotherapy for synovial sarcoma: a retrospective analysis of a Nationwide database in Japan
- Author
-
Xu, Gang, Aiba, Hisaki, Yamamoto, Norio, Hayashi, Katsuhiro, Takeuchi, Akihiko, Miwa, Shinji, Higuchi, Takashi, Abe, Kensaku, Taniguchi, Yuta, Araki, Yoshihiro, Saito, Shiro, Yoshimura, Kenichi, Murakami, Hideki, Tsuchiya, Hiroyuki, and Kawai, Akira
- Published
- 2021
- Full Text
- View/download PDF
4. Cancer cells mimic in vivo spatial-temporal cell-cycle phase distribution and chemosensitivity in 3-dimensional Gelfoam® histoculture but not 2-dimensional culture as visualized with real-time FUCCI imaging
- Author
-
Yano, Shuya, Miwa, Shinji, Mii, Sumiyuki, Hiroshima, Yukihiko, Uehara, Fuminaru, Kishimoto, Hiroyuki, Tazawa, Hiroshi, Zhao, Ming, Bouvet, Michael, Fujiwara, Toshiyoshi, and Hoffman, Robert M
- Subjects
Biochemistry and Cell Biology ,Biological Sciences ,Cancer ,Bioengineering ,Animals ,Cell Culture Techniques ,Cell Cycle ,Cell Death ,Cell Line ,Tumor ,Cisplatin ,Computer Systems ,Female ,Fluorescence ,Gelatin Sponge ,Absorbable ,Humans ,Mice ,Nude ,Molecular Imaging ,Neoplasms ,Paclitaxel ,Time Factors ,Ubiquitination ,cell cycle ,chemotherapy ,FUCCI ,Gelfoam ,GFP ,imaging ,RFP ,stomach cancer ,Three dimensional-histoculture culture ,Gelfoam® ,Developmental Biology ,Biochemistry and cell biology - Abstract
The phase of the cell cycle can determine whether a cancer cell can respond to a given drug. We previously reported monitoring of real-time cell cycle dynamics of cancer cells throughout a live tumor, intravitally in live mice, using a fluorescence ubiquitination-based cell-cycle indicator (FUCCI). Approximately 90% of cancer cells in the center and 80% of total cells of an established tumor are in G0/G1 phase. Longitudinal real-time imaging demonstrated that cytotoxic agents killed only proliferating cancer cells at the surface and, in contrast, had little effect on quiescent cancer cells, which are the vast majority of an established tumor. Moreover, resistant quiescent cancer cells restarted cycling after cessation of chemotherapy. These results suggested why most drugs currently in clinical use, which target cancer cells in S/G2/M, are mostly ineffective on solid tumors. In the present report, we used FUCCI imaging and Gelfoam® collagen-sponge-gel histoculture, to demonstrate in real time, that the cell-cycle phase distribution of cancer cells in Gelfoam® and in vivo tumors is highly similar, whereby only the surface cells proliferate and interior cells are quiescent in G0/G1. This is in contrast to 2D culture where most cancer cells cycle. Similarly, the cancer cells responded similarly to toxic chemotherapy in Gelfoam® culture as in vivo, and very differently than cancer cells in 2D culture which were much more chemosensitive. Gelfoam® culture of FUCCI-expressing cancer cells offers the opportunity to image the cell cycle of cancer cells continuously and to screen for novel effective therapies to target quiescent cells, which are the majority in a tumor and which would have a strong probability to be effective in vivo.
- Published
- 2015
5. Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy
- Author
-
Yano, Shuya, Zhang, Yong, Zhao, Ming, Hiroshima, Yukihiko, Miwa, Shinji, Uehara, Fuminari, Kishimoto, Hiroyuki, Tazawa, Hiroshi, Bouvet, Michael, Fujiwara, Toshiyoshi, and Hoffman, Robert M
- Subjects
Cancer ,Animals ,Antineoplastic Agents ,Cell Line ,Tumor ,Humans ,Interphase ,Mice ,Mice ,Nude ,Salmonella typhimurium ,Stomach Neoplasms ,Time-Lapse Imaging ,Xenograft Model Antitumor Assays ,cell cycle ,chemotherapy ,decoy ,FUCCI ,GFP ,RFP ,imaging ,S ,typhimurium A1-R ,tumor-targeting bacteria ,fluorescence ubiquitination-based cell cycle indicator ,typhimurium ,GFP ,RFP ,imaging ,S. typhimurium A1-R ,fluorescence ubiquitination-based cell cycle indicator ,S. typhimurium ,Biochemistry and Cell Biology ,Developmental Biology - Abstract
Quiescent cancer cells are resistant to cytotoxic agents which target only proliferating cancer cells. Time-lapse imaging demonstrated that tumor-targeting Salmonella typhimurium A1-R (A1-R) decoyed cancer cells in monolayer culture and in tumor spheres to cycle from G0/G1 to S/G2/M, as demonstrated by fluorescence ubiquitination-based cell cycle indicator (FUCCI) imaging. A1-R infection of FUCCI-expressing subcutaneous tumors growing in nude mice also decoyed quiescent cancer cells, which were the majority of the cells in the tumors, to cycle from G0/G1 to S/G2/M, thereby making them sensitive to cytotoxic agents. The combination of A1-R and cisplatinum or paclitaxel reduced tumor size compared with A1-R monotherapy or cisplatinum or paclitaxel alone. The results of this study demonstrate that A1-R can decoy quiescent cancer cells to cycle to S/G2/M and sensitize them to cytotoxic chemotherapy. These results suggest a new paradigm of bacterial-decoy chemotherapy of cancer.
- Published
- 2014
6. Fluorescence‐guided surgery improves outcome in an orthotopic osteosarcoma nude‐mouse model
- Author
-
Miwa, Shinji, Hiroshima, Yukihiko, Yano, Shuya, Zhang, Yong, Matsumoto, Yasunori, Uehara, Fuminari, Yamamoto, Mako, Kimura, Hiroaki, Hayashi, Katsuhiro, Bouvet, Michael, Tsuchiya, Hiroyuki, and Hoffman, Robert M
- Subjects
Rare Diseases ,Cancer ,Animals ,Bone Neoplasms ,Cisplatin ,Disease Models ,Animal ,Female ,Fluorescence ,Lung Neoplasms ,Mice ,Nude ,Osteosarcoma ,Treatment Outcome ,osteosarcoma ,RFP ,fluorescence-guided surgery ,orthotopic mouse model ,chemotherapy ,cisplatinum ,Biomedical Engineering ,Clinical Sciences ,Human Movement and Sports Sciences ,Orthopedics - Abstract
In order to develop a model for fluorescence-guided surgery (FGS), 143B human osteosarcoma cells expressing red fluorescent protein (RFP) were injected into the intramedullary cavity of the tibia in nude mice. The fluorescent areas of residual tumors after bright-light surgery (BLS) and FGS were 10.2 ± 2.4 mm(2) and 0.1 ± 0.1 mm(2) , respectively (p
- Published
- 2014
7. Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis
- Author
-
Saito, Shiro, Aiba, Hisaki, Yamada, Satoshi, Okamoto, Hideki, Hayashi, Katsuhiro, Kimura, Hiroaki, Miwa, Shinji, Otsuka, Takanobu, and Murakami, Hideki
- Published
- 2020
- Full Text
- View/download PDF
8. Outcomes of Window Therapy with Carboplatin and Ifosfamide for Pediatric Osteosarcoma: A Case Series.
- Author
-
Aiba, Hisaki, Kamei, Michi, Ito, Yasuhiko, Takeda, Risa, Yamada, Satoshi, Okamoto, Hideki, Hayashi, Katsuhiro, Miwa, Shinji, Kawaguchi, Yohei, Saito, Shiro, Sakai, Takao, Murakami, Hideki, and Kimura, Hiroaki
- Subjects
PATIENT aftercare ,CARBOPLATIN ,ACADEMIC medical centers ,OSTEOSARCOMA ,CANCER chemotherapy ,IFOSFAMIDE ,RETROSPECTIVE studies ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,COMBINED modality therapy ,PATIENT safety ,CHILDREN - Abstract
For the treatment of osteosarcoma, cisplatin (CDDP) can be substituted by carboplatin (CBDCA) to reduce toxicity. We report a single institution experience of CBDCA-based regimen. Two to three cycles of CBDCA + ifosfamide (IFO) therapy (window therapy) were administered as neoadjuvant therapy for osteosarcoma. Depending on the response of window therapy, the subsequent protocols were determined; for good responders, surgery is performed, and postoperative therapies with CBDCA + IFO, adriamycin (ADM) and high-dose methotrexate (MTX) were administered; for stable disease, the postoperative regimens were advanced before surgery, and the remaining amount of postoperative chemotherapy is deduced; for progressive disease, CBDCA-based regimen is changed to CDDP-based regimen. From 2009 to 2019, seven patients were treated with this protocol. During the window therapy, two patients (28.6%) were assessed as good responders and completed the regimen as planned. Four patients (57.1%) had stable disease, and the chemotherapy schedules were modified. One patient (14.2%) with progressive disease was shifted to the CDDP-based regimen. At final follow-up, four patients showed no evidence of disease and three patients died of the disease. Since the efficacy during window therapy was limited, a CBDCA-based regimen in the neoadjuvant setting was considered insufficient for performing adequate surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Reconstruction using a frozen autograft for a skull and humeral lesion of synchronous multicentric osteosarcoma after undergoing successful neoadjuvant chemotherapy: a case report and review of the literature.
- Author
-
Yoshihiro Araki, Katsuhiro Hayashi, Norio Yamamoto, Akihiko Takeuchi, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Kensaku Abe, Yuta Taniguchi, Hirotaka Yonezawa, Sei Morinaga, Yohei Asano, Takayuki Nojima, Hiroyuki Tsuchiya, Araki, Yoshihiro, Hayashi, Katsuhiro, Yamamoto, Norio, Takeuchi, Akihiko, Miwa, Shinji, and Igarashi, Kentaro
- Abstract
Background: Synchronous multicentric osteosarcoma (SMOS) is a rare disease characterized by simultaneous multicentricity of intraosseous osteosarcoma without visceral involvement. SMOS, including a skull lesion, which occurs relatively rarely, and reconstruction using a frozen autograft after the excision of a lesion of SMOS has been infrequently reported previously.Case Presentation: We report an 18-year-old girl with SMOS, with lesions located in the left distal femur, right proximal humerus, and left occipital bone. Her major complaint was pain and swelling around the left knee joint. Asymptomatic lesions of the humerus and skull bone were detected on a systemic bone scan. No visceral organ metastasis was observed. A biopsy of the distal femoral lesion revealed osteosarcoma. Based on the histological findings, multiple bone lesions, and absence of visceral lesion, the clinical diagnosis of SMOS was made. After five courses of neoadjuvant chemotherapy with a regimen of doxorubicin and cisplatin, reconstruction using a tumor prosthesis following wide excision of the left distal femur was performed, and total necrosis was histologically observed in the retracted specimen. Following three cycles of adjuvant chemotherapy, tumor excision and reconstruction with a frozen autograft treated with liquid nitrogen was conducted for both lesions of the humerus and skull, rather than tumor prosthesis or synthetics, in order to retain a normal shoulder function, and to obtain a good cosmetic and functional outcome after treatment of the skull lesion. Further adjuvant chemotherapy could not be administered after the completion of the surgical treatment for all lesions because the adverse events due to chemotherapy were observed. At over 5 years after the diagnosis, she remains clinically disease-free.Conclusions: An early correct diagnosis, the proper management of chemotherapy, and surgical treatment for all lesions are essential for achieving a good clinical outcome, even in SMOS including a skull lesion. By performing reconstruction using a frozen autograft for a proximal humeral lesion and a skull lesion after confirming the good histological efficacy of neoadjuvant chemotherapy for the primary lesion, the excellent function of the shoulder joint and a good cosmetic outcome at the site of the skull lesion was acquired without complications or recurrence. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
10. Preoperative evaluation of the efficacy of radio-hyperthermo-chemotherapy for soft tissue sarcoma in a case series.
- Author
-
Aiba, Hisaki, Yamada, Satoshi, Mizutani, Jun, Yamamoto, Norio, Okamoto, Hideki, Hayashi, Katsuhiro, Kimura, Hiroaki, Takeuchi, Akihiko, Miwa, Shinji, Higuchi, Takashi, Abe, Kensaku, Taniguchi, Yuta, Araki, Yoshihiro, Tsuchiya, Hiroyuki, and Otsuka, Takanobu
- Subjects
SOFT tissue tumors ,DISEASE relapse ,CANCER chemotherapy ,DRUG efficacy ,NEEDLE biopsy ,TUMOR treatment - Abstract
Purpose: Radio-hyperthermo-chemo (RHC) therapy, which combines radiotherapy, hyperthermia, and chemotherapy, for malignant soft tissue tumors has been introduced with the aim of decreasing the possibility of local recurrence after surgery. To avoid unnecessary neoadjuvant therapy and to plan the appropriate surgical treatment, surveillance of RHC therapeutic efficacy during treatment is necessary. In this study, we determined the optimal response criteria to evaluate the efficacy of RHC by comparing preoperative images before and after RHC with pathological evaluation of necrosis in the resected tumor. Patients and methods: From 2004 to 2014, 20 patients were enrolled into this study. Needle biopsy revealed 6 cases of myxoid liposarcoma, 6 cases of undifferentiated pleomorphic sarcoma, 4 cases of myxofibrosarcoma, and 4 cases of synovial sarcoma. Based on the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or modified RECIST, we calculated the responses to RHC therapy by comparing pre- and post-RHC therapy images. In addition, resected specimens underwent pathological analysis to evaluate response based on tumor necrosis. The correlation between assessment based on preoperative images and resected tumors were evaluated by the Spearman’s rank-order correlation coefficient. Result: From the surgical specimens, pathological assessment of necrosis in resected tumor were assessed as less than 50% (2 cases), 50–90% (9 cases), 90–99% (6 cases), and total necrosis (3 cases). Use of the RECIST 1.1 underestimated good responders as stable disease (SD) or progressive disease (PD) in 5 out of 15 cases; on the other hand, use of the modified RECIST did not underestimate the pathological assessment of necrosis. The correlations between responses based on preoperative images and those based on histological assessments were 0.23 (RECIST 1.1) and 0.76 (modified RECIST). Conclusion: Because pathological responses can be underestimated using the RECIST 1.1, the modified RECIST, which take into consideration tumor viability, as assessed by contrast MRI, should also be considered when evaluating the efficacy of RHC. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Risk factors for postoperative deep infection in bone tumors.
- Author
-
Miwa, Shinji, Shirai, Toshiharu, Yamamoto, Norio, Hayashi, Katsuhiro, Takeuchi, Akihiko, Tada, Kaoru, Kajino, Yoshitomo, Inatani, Hiroyuki, Higuchi, Takashi, Abe, Kensaku, Taniguchi, Yuta, and Tsuchiya, Hiroyuki
- Subjects
- *
BONE surgery , *SURGICAL complications , *ONCOLOGIC surgery , *CANCER chemotherapy - Abstract
Background: Postoperative deep infection after bone tumor surgery remains a serious complication. Although there are numerous reports about risk factors for postoperative deep infection in general surgery, there is only a small number of reports about those for bone tumor surgery. This retrospective study aimed to identify risk factors for postoperative deep infection after bone tumor resection. Methods: We reviewed data of 681 patients (844 bone tumors) who underwent surgery. Associations between variables, including age, recurrent tumor, pathological fracture, surgical site (pelvis/other), chemotherapy, biological reconstruction, augmentation of artificial bone or bone cement, the use of an implant, intraoperative blood loss, operative time, additional surgery for complications, and postoperative deep infection were evaluated. Results: The rate of postoperative deep infection was 3.2% (27/844 tumors). A pelvic tumor (odds ratio [OR]: 3.4, 95% confidence interval [CI]: 1.0–11.3) and use of an implant (OR: 9.3, 95% CI: 1.9–45.5) were associated with an increased risk of deep infection. Conclusions: This retrospective study showed that pelvic tumor and use of an implant were independent risk factors for deep infection. This information will help surgeons prepare an adequate surgical plan for patients with bone tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
12. Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
- Author
-
Miwa, Shinji, Yamamoto, Norio, Hayashi, Katsuhiro, Takeuchi, Akihiko, Igarashi, Kentaro, and Tsuchiya, Hiroyuki
- Subjects
- *
CHONDROSARCOMA , *DRUG target , *THERAPEUTICS , *ANTINEOPLASTIC agents , *TREATMENT effectiveness , *ISOLATION perfusion - Abstract
Simple Summary: Chondrosarcomas develop chemoresistance to standard anticancer drugs, making it difficult to control unresectable or metastatic chondrosarcomas. To improve the clinical outcomes of chondrosarcoma, new treatment approaches, such as molecule-targeting agents and immunotherapy, are needed. Recent research has revealed promising biomarkers and therapeutic targets for chondrosarcoma. In addition, several molecule-targeting agents have shown favorable antitumor activities in several clinical studies in patients with advanced sarcomas, including chondrosarcoma. This review summarizes recent basic studies on biomarkers and therapeutic targets and recent clinical studies on treating chondrosarcomas. Due to resistance to standard anticancer agents, it is difficult to control the disease progression in patients with metastatic or unresectable chondrosarcoma. Novel therapeutic approaches, such as molecule-targeting drugs and immunotherapy, are required to improve clinical outcomes in patients with advanced chondrosarcoma. Recent studies have suggested several promising biomarkers and therapeutic targets for chondrosarcoma, including IDH1/2 and COL2A1. Several molecule-targeting agents and immunotherapies have shown favorable antitumor activity in clinical studies in patients with advanced chondrosarcomas. This review summarizes recent basic studies on biomarkers and molecular targets and recent clinical studies on the treatment of chondrosarcomas. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma.
- Author
-
Miwa, Shinji, Yamamoto, Norio, Hayashi, Katsuhiro, Takeuchi, Akihiko, Igarashi, Kentaro, and Tsuchiya, Hiroyuki
- Subjects
- *
ANTINEOPLASTIC agents , *CANCER chemotherapy , *CANCER patients , *COMBINATION drug therapy , *IMMUNOTHERAPY , *MEDICAL research , *METASTASIS , *MOLECULAR biology , *RADIOTHERAPY , *RHABDOMYOSARCOMA , *SOFT tissue tumors , *OPERATIVE surgery , *TUMORS in children , *VINCRISTINE , *TREATMENT effectiveness , *CYCLOPHOSPHAMIDE , *DACTINOMYCIN , *IFOSFAMIDE - Abstract
Rhabdomyosarcoma, the most common soft tissue sarcoma noted in childhood, requires multimodality treatment, including chemotherapy, surgical resection, and/or radiation therapy. The majority of the patients with localized rhabdomyosarcoma can be cured; however, the long-term outcomes in patients with metastatic rhabdomyosarcoma remain poor. The standard chemotherapy regimen for patients with rhabdomyosarcoma is the combination of vincristine, actinomycin, and cyclophosphamide/ifosfamide. In recent clinical trials, modifications of the standard chemotherapy protocol have shown improvements in the outcomes in patients with rhabdomyosarcoma. In various type of malignancies, new treatments, such as molecular targeted drugs and immunotherapies, have shown superior clinical outcomes compared to those of standard treatments. Therefore, it is necessary to assess the benefits of these treatments in patients with rhabdomyosarcoma. Moreover, recent basic and clinical studies on rhabdomyosarcoma have reported promising therapeutic targets and novel therapeutic approaches. This article reviews the recent challenges and advances in the management of rhabdomyosarcoma. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Treatment of a Malignant Soft Tissue Tumor Arising in the Vicinity of the Sciatic Nerve with an In-Situ Preparation Technique and Intensive Multidisciplinary Therapy.
- Author
-
Aiba, Hisaki, Hayashi, Katsuhiro, Yamada, Satoshi, Okamoto, Hideki, Kimura, Hiroaki, Miwa, Shinji, Inatani, Hiroyuki, Otsuka, Takanobu, and Murakami, Hideki
- Subjects
CANCER treatment ,COMBINED modality therapy ,SARCOMA ,SCIATIC nerve ,SOFT tissue tumors ,THIGH ,CHEMORADIOTHERAPY ,TUMOR treatment - Abstract
Preservation of the sciatic nerve is difficult in cases of highly malignant soft tissue tumors closely surrounding the nerve. Herein, we present the first case of preservation of this nerve by combining an in-situ preparation technique (ISP; a technique enabling the preparation of neurovascular bundles without contamination by tumor cells) with intensive concurrent neoadjuvant chemo-radiotherapy with hyperthermia (RHC; radio-hyperthermo-chemotherapy). A 62-year-old man presented with a soft tissue mass in the right thigh and was diagnosed with undifferentiated pleomorphic sarcoma. The tumor arose in the multi-compartment areas of the posterior thigh muscles and was closely intertwined with the sciatic nerve. As preoperative therapy, RHC was performed for surgical down-staging and the tumor partially responded. Afterwards, wide resection of the tumor with preservation of the sciatic nerve using ISP was performed. Following the surgery, there has not been recurrence in the affected site and the functional outcomes of the lower extremity achieved 80% in the Musculoskeletal Tumor Society score. The patient is still alive with disease five years postoperatively. This is the first case in which ISP and RHC procedures were combined for the preservation of the neurovascular structure. Further study is needed for the validation of the feasibility of this method. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
- Author
-
Miwa, Shinji, Yamamoto, Norio, Hayashi, Katsuhiro, Takeuchi, Akihiko, Igarashi, Kentaro, and Tsuchiya, Hiroyuki
- Subjects
- *
NEOVASCULARIZATION , *APOPTOSIS , *IMMUNOTHERAPY , *METASTASIS , *TRABECTEDIN - Abstract
Due to the rarity and heterogeneity of bone and soft-tissue sarcomas, investigation into molecular targets and new treatments has been particularly challenging. Although intensive chemotherapy and establishment of surgical procedures have improved the outcomes of patients with sarcoma, the curative rate of recurrent and metastatic sarcomas is still not satisfactory. Recent basic science research has revealed some of the mechanisms of progression and metastasis of malignancies including proliferation, apoptosis, angiogenesis, tumor microenvironment, migration, invasion, and regulation of antitumor immune systems. Based on these basic studies, new anticancer drugs, including pazopanib, trabectedin, eribulin, and immune checkpoint inhibitors have been developed and the efficacies and safety of the new drugs have been assessed by clinical trials. This review summarizes new molecular therapeutic targets and advances in the treatment for bone and soft tissue sarcomas. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.